Kactus Biosystems
PrivateLast Round
Series B
Oct 20, 2022
Est. Valuation
$21.3M
Total Funding Raised
$55.31M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kactus Biosystems is a biotechnology company that specializes in protein engineering and manufacturing, providing recombinant proteins, GMP-grade enzymes, and custom contract research services for drug discovery, immunotherapy, gene editing, and mRNA therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kactus Biosystems Comparables
Compare Kactus Biosystems with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BPS Bioscience | 85% | |
| ACROBiosystems | 82% | |
| ProSpec-Tany TechnoGene | 81% | |
Kactus Biosystems Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 20, 2022 | ||||
| Series A Extension | Jul 11, 2021 | ||||
| Series A | Sep 28, 2020 | ||||
| Pre Seed | Dec 20, 2018 | ||||
| Angel | Apr 26, 2018 | ||||
Angel | Mar 1, 2018 |
Key People
Founding team and executive leadership
Kactus Biosystems Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Alliance Capital | Series B |
| Lingang Blue Bay Capital | Series B |
| Shanghai Guofang Private Equity Fund Management | Series B |
| SDIC Venture Capital | Series A Extension, Series A |
| GF Capital Management & Advisors | Series B |
| Hudson Bay Capital Management | Series A Extension |
| Sherpa Healthcare Partners | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Partnered with AstraGenomics to commercialize gene editing tools.
- Feb 10, 2026
Attending the Festival of Biologics (FOB) USA 2026.
Kactus Biosystems Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Kactus Biosystems's valuation, stock price, and market status.